

Study by Tioga Research Supports Efficacy of Liposomal Compound Silvidiol?



Topical Cannabinoid Delivery System Demonstrates Ability to Permeate Skin to Reach Somatic and Neuropathic Sensory Receptors Without Systemic Exposure

HENDERSON, Nev. ? February 19, 2019 /Canna Newswire/ ? [Leading Edge Pharms, Inc.](#), (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced the results of a [Tioga Research](#)-led study, indicating that its proprietary cannabidiol-based (CBD) pain relief and anti-inflammatory agent, Silvidiol?, effectively permeates the epidermis to reach somatic and neuropathic sensory receptors below the surface of the skin.

The study, directed by Dr. Daniel Holsworth, Ph.D. of StemNext, with Tioga Research, tested the ability of Silvidiol to permeate the epidermis and dermal-epidermal junction layers of the skin, without reaching areas of the dermis where systemic exposure could occur. Silvidiol was evaluated and compared with CBD in dimethylsulfoxide (DMSO), a widely known and effective transdermal carrier of chemicals through the skin for the purpose of entering the bloodstream.

?Through this study, we conclude that Silvidiol, a nano-sized particle compound encapsulated by liposomal carriers, effectively reaches somatic nociceptive and peripheral neuropathic sensory receptor sites in the skin and remains active for up to 24 hours,? explained Dr. Holsworth. ?These findings support the theory Silvidiol's delivery system may improve localized action in the skin to help reduce symptomatic skin, muscle, joint and nerve pain accompanied by inflammation.?

?The independent study conducted by StemNext and Tioga Research support LEP research that indicate CANNAVERA topical products containing Silvidiol are non-systemic and pose limited interaction potential with orally administered OTC. The study also demonstrated Silvidiol's ability to penetrate the outer skin layers and remain bioavailable in the epidermis for 24 hours, making it amenable to point of care therapeutics,? said David Chadwick, CEO of Leading Edge Pharms. ?These results are extremely positive and have led us to strengthen our resolve to continue with research and clinical studies in support of our mission to provide natural, safe and effective topical products to those suffering from acute and chronic periods of pain and inflammation.?

Leading Edge Pharms provided financial support for Tioga Research's testing and evaluation of Silvidiol.

ABOUT LEADING EDGE PHARMS, INC.

Leading Edge Pharms, Inc. (LEP) is a biotechnology company focused on the research, development and commercialization of novel cannabinoid therapies and innovative delivery platforms. LEP is the developer of **CANNAVERA?** pain relief products, available in pharmacies across the United States. All LEP products are manufactured in FDA registered facilities adhering to current Good Manufacturing Practices and are available at www.LENCURA.com. Learn more at www.leadingedge.com.

Follow Leading Edge Pharms on social media:

LinkedIn: [li:/leading-edge-pharms-inc](https://www.linkedin.com/company/leading-edge-pharms-inc) | Twitter: [@LeadEdgePharms](https://twitter.com/LeadEdgePharms)

CNW

Leading Edge Pharms Company Contact:

David Chadwick, CEO
dchadwick@leadingedge.com
(800) 813-0013

Leading Edge Pharms Media Contact:

Nicole Grubner
leadingedge@finnpartners.com
(929) 222-8011